Kitasamycin (INN) is a macrolide antibiotic. It is produced by Streptomyces kitasatoensis. The drug has antimicrobial activity against a wide spectrum of pathogens. Kitasamycin Tartrate In 1953, HATA, et al. reported the isolation of a new antibiotic complex known as kitasamycin (leucomycin). The organism producing this antibiotic complex was obtained from soil samples and named Streptotnyces kitasatoensis HATA. In 1967, eight components were separated and their chemical structures determined. This antibiotic was approved by Ministry of Agriculture in 2001 as the growth promoter additive in poultry and swine to control and prevent digestive and respiratory diseases. Belonging to the macrolide antibiotic, its antibacterial activity is similar to tylosin, erythromycin, spiramycin and oleandomycin. The mode of action is to inhibit the protein synthesis process. Its inhibition spectrum includes Mycoplasmas, Gram-positive bacteria, some Gram-negative bacteria, Leptospira, Rickettsia. It also inhibits most bacteria resistant to penicillin, oxytetracycline, chlortetracycline, erythromycin and chloramphenicol bacteria strains. It is a safe and high efficacy growth-promoting additive for swine and poultry. Although this antibiotic was evaluated many years ago, it was felt of interest to determine its activity against recent isolates of gram-positive cocci. Consequently, the in vitro activity of kitasamycin was determined against 214 gram-positive cocci isolated from clinical specimens. Kitasamycin has activity against the vast majority of clinical isolates of S. aureus, Str. pyogenes and Dipl. pneumoniae, but in vitro studies do not suggest that it has any advantages over currently available antibiotics, although it would be expected to be effective in clinical situations in which erythromycin is indicated.

Semustine is a methylated derivative of carmustine with potent antineoplastic activity. As an alkylating agent, semustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. Semustine is primarily used to treat brain tumors, colorectal tumors, lymphomas, and stomach cancer.

Terlipressin (Glypressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepatorenal syndrome type 1. It is a prodrug and is converted to the lysine vasopressin in the circulation after the N-triglycyl residue is cleaved by endothelial peptidases. This results in a ‘slow release’ of the vasoactive lysine vasopressin. Terlipressin exerts its action by activating V1a, V1b and V2 vasopressin receptors. On September 14, 2022, the FDA granted approval to terlipressin (Terlivaz) for the treatment of adults hospitalized with hepatorenal syndrome with rapid reduction in kidney function (HRS-1). Prior to the approval, no approved treatment for this condition existed in the United States.